Literature DB >> 16617014

Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men.

Teresa W Wilborn1, Nicholas P Lang, Michelle Smith, Sreelatha Meleth, Charles N Falany.   

Abstract

Dehydroepiandrosterone (DHEA) sulfate which is present at micromolar levels in the plasma, can be desulfated to supply free DHEA for metabolism to androgens or estrogens in peripheral tissues. Human cytosolic sulfotransferase (SULT) 2A1 catalyzes DHEA sulfation in the adrenal cortex. Three SULT2A1 nonsynonymous coding single nucleotide polymorphisms (SNPs), identified only in African Americans (AA), are associated with decreased levels of activity and expression as compared to wild-type cDNA when expressed in COS cells. To test whether the SNPs are associated with decreased plasma androgens, 124 normal AA men were genotyped and plasma DHEA, DHEA-sulfate and testosterone levels determined. The two SNPs identified in these participants occurred at allelic frequencies of 0.044 (G187C) and 0.101 (G781A). The G187C SNP was highly linked to the G781A SNP. Although no differences in hormone levels were associated with the individual SNPs, a significant increase in the DHEA:DHEA-sulfate ratio was observed in participants with a heterozygous G187C/G781A genotype. Increased free DHEA levels may result in increased testosterone synthesis and stimulation in the prostate, therefore a group of AA prostate cancer (PC) patients and controls were genotyped. No significant association of the presence of the different SULT2A1 alleles with the occurrence of PC was detected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617014     DOI: 10.1016/j.jsbmb.2006.01.006

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer.

Authors:  Dongfang Tang; Yu C Zhao; Hongliang Liu; Sheng Luo; Jeffrey M Clarke; Carolyn Glass; Li Su; Sipeng Shen; David C Christiani; Wen Gao; Qingyi Wei
Journal:  Int J Cancer       Date:  2020-03-09       Impact factor: 7.396

2.  Pregnane X receptor as a therapeutic target to inhibit androgen activity.

Authors:  Bin Zhang; Qiuqiong Cheng; Zhimin Ou; Jung Hoon Lee; Meishu Xu; Upasana Kochhar; Songrong Ren; Min Huang; Beth R Pflug; Wen Xie
Journal:  Endocrinology       Date:  2010-10-20       Impact factor: 4.736

3.  Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.

Authors:  Erika M Kwon; Sarah K Holt; Rong Fu; Suzanne Kolb; Gabrielle Williams; Janet L Stanford; Elaine A Ostrander
Journal:  Cancer Epidemiol       Date:  2012-04-26       Impact factor: 2.984

4.  Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.

Authors:  Elahe A Mostaghel; Brett T Marck; Orpheus Kolokythas; Felix Chew; Evan Y Yu; Michael T Schweizer; Heather H Cheng; Phillip W Kantoff; Steven P Balk; Mary-Ellen Taplin; Nima Sharifi; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2021-08-18       Impact factor: 12.531

Review 5.  Review of studies on metabolic genes and cancer in populations of African descent.

Authors:  Camille C Ragin; Scott Langevin; Scott Rubin; Emanuela Taioli
Journal:  Genet Med       Date:  2010-01       Impact factor: 8.822

6.  Sex-, Age-, and Race/Ethnicity-Dependent Variations in Drug-Processing and NRF2-Regulated Genes in Human Livers.

Authors:  Jie Liu; Julia Yue Cui; Yuan-Fu Lu; J Christopher Corton; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2020-11-08       Impact factor: 3.922

Review 7.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

8.  A SULT2A1 genetic variant identified by GWAS as associated with low serum DHEAS does not impact on the actual DHEA/DHEAS ratio.

Authors:  Robin Haring; Henri Wallaschofski; Alexander Teumer; Heyo Kroemer; Angela E Taylor; Cedric H L Shackleton; Matthias Nauck; Uwe Völker; Georg Homuth; Wiebke Arlt
Journal:  J Mol Endocrinol       Date:  2012-12-31       Impact factor: 5.098

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.